Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke
 
Status In progress
Process MTA
Referral date 01 December 2014
Description

Scoped as part of Batch 38

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Associate Director: Helen Knight
Communications manager: TBC
Project manager:

Kate Moore

Technical Advisor: TBC
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
18 October 2016 The Department of Health has asked us to carry out a Multiple Technology Appraisal of botulinum toxin type A preparations (Botox, Dysport, and Xeomin) within their marketing authorisations for treating upper or lower limb focal spasticity associated with stroke. This appraisal involves a number of companies and as the appraisal will be covering the treatment for upper or lower focal spasticity there are a broad range of licenses. NICE therefore has to ensure that all products will be licensed at the appropriate point in the appraisal. Taking all of these points into account and in order to undertake this appraisal efficiently whilst providing the best value to the NHS the appraisal will be rescheduled. The revised timelines will be available in due course.
24 June 2015 Please note that following on from updates received from some of the companies this appraisal has been rescheduled in order to align with the latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late January 2017when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid May 2017.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance